Trial Profile
A phase III study to evaluate 24- and 48-week response-guided treatment with telaprevir in combination with VX 222, pegylated interferon alpha 2a, and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C and cirrhosis.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2011
Price :
$35
*
At a glance
- Drugs Interferon alpha-2a (Primary) ; Lomibuvir (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 09 Nov 2011 New trial record